Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Regorafenib in Stage IV Colorectal Cancer After Curative Liver Resection
NCT01939223Phase 3Terminated
- Sponsor
- Bayer
- Start
- Dec 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Regorafenib with Placebo (2 arms). Primary endpoint: Disease Free Survival. Started Dec 2013; status: terminated.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01939223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939223.